secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2026-05-13T10:35:21+00:00
Accession:  0001104659-26-059734
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Q1 net loss $3.3M ($0.22/sh); cash $46.5M; APR-1051 shows two partial responses
--------------------------------------------------------------------------------

- Cash and equivalents $46.5M as of Mar 31, 2026, up from $14.6M year-end 2025; runway into Q1 2028.
- Operating loss $3.4M for Q1 2026 vs $4.1M in Q1 2025; R&D expense fell to $1.6M from $2.5M.
- WEE1 inhibitor APR-1051: two partial responses observed; dose escalation ongoing; ASCO 2026 presentation on May 30.
- Oversubscribed $30M private placement closed Mar 31, 2026, led by Soleus Capital to expand APR-1051 enrollment.
- ATRN-119 (ATR inhibitor) monotherapy paused; evaluating combination approaches including with radiation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/0001104659-26-059734-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-059734

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer